In vitro studies have shown that inhibition of ribosomal biogenesis can activate p53 through ribosomal protein (RP)-mediated suppression of Mdm2 E3 ligase activity. To study the physiological significance of the RP-Mdm2 interaction, we generated mice carrying a cancer-associated cysteine-to-phenylalanine substitution in the zinc finger of Mdm2 that disrupted its binding to RPL5 and RPL11. Mice harboring this mutation, retain normal p53 response to DNA damage, but lack of p53 response to perturbations in ribosome biogenesis. Loss of RP-Mdm2 interaction significantly accelerates Em-Myc-induced lymphomagenesis. Furthermore, ribosomal perturbation-induced p53 response does not require tumor suppressor p19ARF. Collectively, our findings establish RP-Mdm2 interaction as a genuine p53 stress-signaling pathway activated by aberrant ribosome biogenesis and essential for safeguarding against oncogenic c-MYC-induced tumorigenesis.
INTRODUCTION
The p53 transcription factor interacts with a large number of proteins and plays a central role in regulating cell growth, proliferation, and apoptosis (Vogelstein et al., 2000) . The function of p53 is negatively controlled by Mdm2 (HDM2 in humans, henceforth as Mdm2), which itself is a transcriptional target of p53, thus constituting an auto regulatory feedback loop (Picksley and Lane, 1993) . Mdm2 controls the activity of p53 and is regulated in response to a multitude of stressors, one of these stressors is the so-called nucleolar stress (also known as ribosomal stress) (Rubbi and Milner, 2003) . Previous evidence demonstrates a nucleolar stress response to a low dose (5 nM) of actinomycin D (Act D) Jin et al., 2004) , 5-fluorouracil (5-FU) (Gilkes et al., 2006; Sun et al., 2007) , serum depletion and contact inhibition (Bhat et al., 2004) , mycophenolic acid (MPA)-mediated depletion of GTP , or interfering with nucleolar function by ectopic overexpression of nucleostemin . At low concentrations (e.g., <10 nM), Act D selectively inhibits ribosomal biogenesis through inhibiting pol I-dependent transcription of rRNA (Iapalucci-Espinoza and Franze-Fernandez, 1979; Perry and Kelley, 1970) . 5-FU is a pyrimidine analog whose metabolite, FUTP, is extensively incorporated into RNA, disrupting normal RNA processing (Longley et al., 2003) .
MPA inhibits de novo guanine nucleotide biosynthesis, leading
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to depletion of intracellular guanine nucleotide and blockage of de novo RNA synthesis (Allison, 2005) . As the prime location for ribosome biogenesis, the nucleolus is highly susceptible to perturbations in the process of ribosome assembly, thereby clarifying how nucleolar stress is often synonymous with ''ribosomal stress. '' Ribosome biogenesis is an essential cellular process that involves three fundamental steps: coordinated expression of ribosomal RNA (rRNA) and ribosomal protein (RP), processing of rRNA, and assembly of the 40S and 60S ribosome subunits (Perry, 2007) . Perturbation of any step in this process is thought to lead to nucleolar stress, triggering specific binding of Mdm2 to several RPs, including L11 (Fumagalli et al., 2009; Lohrum et al., 2003; Zhang et al., 2003) , L23 Jin et al., 2004) , and L5 . Increased binding of ribosomal proteins to Mdm2 leads to p53 stability and transactivation. In addition to L5, L11, and L23, additional ribosomal proteins such as S7 (Chen et al., 2007; Zhu et al., 2009 ) and L26 (Ofir-Rosenfeld et al., 2008) have also been shown to interact with Mdm2. The consequence of the S7-Mdm2 interaction resembles that of the other RPs in terms of binding to Mdm2 and activation of p53. However, surprising findings show that MdmX, a homolog of Mdm2, can facilitate S7's suppression of Mdm2 and that S7, itself a substrate for Mdm2 ubiquitination, acts as both an effector and affector of Mdm2 (Zhu et al., 2009) . The interaction of L26 with Mdm2 appears to perform a different function. L26 was found to increase the translational rate of p53 mRNA through binding to its 5 0 untranslated region (UTR) and in this case Mdm2 acts as an E3 ubiquitin ligase for ubiquitylation and degradation of L26, thereby inhibiting p53 translation (Ofir-Rosenfeld et al., 2008) . Collectively, these findings indicate that RPs could play a pivotal role in mediating a p53 response to nucleolar stress (reviewed in Zhang and Lu, 2009) .
Mdm2 contains three highly conserved regions: the N terminus, the C terminus, and the central zinc finger area. The N-terminal conserved domain is important for p53 binding. The C-terminal domain contains a RING finger essential for the E3 ubiquitin ligase function of Mdm2. The function of the central acidic domain, including a highly conserved C4 zinc finger, is not fully understood. Intriguingly, several small basic proteins that function to inhibit Mdm2, including p19ARF and each of the aforementioned ribosomal proteins, all interact with the conserved central acidic domain of Mdm2 ( Figure 1A ), suggesting that this region might serve as a site for receiving and integrating various Mdm2-regulatory signals into the p53 pathway (Dai et al., 2006) . mdm2 gene amplification is the predominant mechanism ascribed to oncogenic activation and has been detected in many types of human cancers including soft tissue sarcomas (Oliner et al., 1992 ) and brain tumors (Corvi et al., 1995; Reifenberger et al., 1993) . In addition to gene amplification and protein overexpression, mutations within the mdm2 gene have been reported in several types of human cancers (Schlott et al., 1997; Tamborini et al., 2001) . Intriguingly, many of the cancer associated Mdm2 mutations occur at or near the central zinc finger, including point mutations altering one of the conserved zinc-coordinating cysteines and truncations around the zinc finger. In vitro studies have shown that mutations at the zinccoordinating cysteine residues disrupts Mdm2 binding to L5 and L11, and as a result diminishes the capacity of Mdm2 to respond to nucleolar stress (Lindstrom et al., 2007) . However, despite recent evidence from multiple laboratories corroborating a putative RP-Mdm2-p53 signaling pathway, the validity of RP mediated signaling to p53 has yet to be demonstrated in vivo. The current study was designed to investigate this.
RESULTS

Generation of Mdm2 C305F Mice
To investigate the physiological relevance of zinc finger mutation, we generated mice bearing a cancer-associated Cys-toPhe substitution in one of the zinc-coordinating residues of Mdm2. The targeting construct, containing a C305F substitution and a new Spe1 restriction site ( Figure 1B ), was recombined into the mdm2 locus of 129/Sv embryonic stem (ES) cells. Successful targeting of mdm2 allele was identified by Southern blotting of genomic DNA isolated from the ES cells ( Figure 1C ), and was confirmed by Spe1 digestion of PCR-amplified genomic DNA ( Figure 1D ). The ES cells were microinjected into C57BL/6 blastocysts to produce chimeras. Chimera males were mated with C57BL/6 females to produce germline transmission of the Mdm2 C305F allele. The targeted allele was reconfirmed through direct sequencing of the genomic DNA after germline transmission was obtained (data not shown Figure 1E ). A survival study was carried out to examine the effect of Mdm2 C305F mutation on longevity. At least 17 animals were included for each genotype, 2-4 animals of the same sex were housed in each cage, and the longevity of these mice were monitored over a 900-day period. Kaplan-Meier survival curve shows a similar survival rate among wild-type, Mdm2 +/C305F and Mdm2 C305F/C305F mice ( Figure 1F ). Additionally, Mdm2 +/C305F or Mdm2 C305F/C305F mice did not exhibit noticeable differences in body weight, pathophysiological defects or predisposition to spontaneous tumors from those of the wild-type mice.
Mdm2
C305F Mutation Disrupts L5 and L11 Binding
To examine the binding activity of the endogenous Mdm2 C305F mutant protein, mouse embryonic fibroblasts (MEFs) were isolated at embryonic day 13.5 (E13.5) and an immunoprecipitation-coupled western blot (IP-western) assay was carried out. Consistent with previous in vitro studies (Lindstrom et al., 2007) , Mdm2 C305F failed to bind L5 and L11 ( Figure 2A ). In contrast, Mdm2
C305F was able to bind L23 and p53 ( Figures   2A and 2B , we carried out p53 half-life assay using early-passage MEF cells. The halflife of p53 was $30 min under unstressed conditions in both wild-type and Mdm2 C305F mutant cells ( Figure 2C ). Likewise, the half-life of Mdm2 itself was found to be also comparable in both wild-type and mutant cells, at $10 min ( Figure 2D ). Thus, the C305F mutation in the zinc finger does not affect the degradation of p53 or Mdm2 itself. We have noticed that the typical doublet-banding pattern of Mdm2 was somewhat altered by the zinc finger mutation, with the mutant Mdm2 C305F showing a stronger top band whereas the wild-type Mdm2 showing a stronger bottom band ( Figure 2D ). The nature of the alteration remains to be clarified. Figure 3B ). Importantly, the levels of Mdm2 and p21 were very comparable between the wild-type and the mutant cells at each corresponding Dox dosage.
We next examined p53 response to DNA damage in mouse tissues. Mouse whole-body g-irradiation causes p53-dependent growth arrest and apoptosis in organs that are sensitive to radiation, such as intestinal epithelium, spleen, bone marrow, and thymus (Bouvard et al., 2000) . Differential responses to irradiation reflect changes of p53 function and can be used as a test for p53 activity in vivo (Komarova et al., 2000) . We subjected mice to 8-Gy whole-body g-irradiation, and the stabilization and activation of p53 was assessed in thymus and spleen 18 hr posttreatment. As shown in Figure 3C , the level of p53 was slightly increased after g-irradiation in both spleen and thymus. The level of p21, on the other hand, was significantly increased, and the increase was similar in organs of the wild-type and the Mdm2 C305F/C305F mice, consistent with results from MEF cells.
We have noticed that the basal levels of p53 and p21 in unstressed mutant organs are somewhat elevated, the reason for which has not been determined. We also investigated DNA damage-induced apoptosis by TUNEL assay. With g-irradiation, extensive apoptosis was observed and the levels of apoptosis in organs isolated from wild-type and Mdm2 C305F/C305F mice were essentially identical ( Figure 3D ). Together, these results support a notion that the p53 DNA damage response is not affected by Mdm2 C305F mutation. . MEFs were treated and analyzed as in (C) for Mdm2.
Mdm2
C305F Mutation Attenuates p53 Response to Ribosome Biogenesis Stress Given that the Mdm2 C305F mutant protein does not interact with L5 and L11 (Figure 2 ), we sought to determine if a low level Act D-induced p53 activation might be attenuated. First, we examined a time-course induction of p53 in MEFs. We observed induction of p53 in the wild-type MEFs within 1-2 hr of Act D treatment that was further increased and sustained until termination of the experiment at 12 hr ( Figure 4A ). In contrast, only a slight induction of p53 at 2 and 4 hr time points was observed Mdm2 C305F/C305F MEFs ( Figure 4A ). The intensity of p53 induction correlated with Mdm2 C305F gene dosage with the wild-type cells exhibiting the highest level of p53 induction and the heterozygous cells showing an intermediate induction ( Figure 4B ). Moreover, we found that a high dose of Act D, 200 nM, elicited equivalent p53 response in MEFs of all genotypes ( Figure 4C ), consistent with a notion that Act D at this concentration causes DNA double strand breaks (Ljungman et al., 1999) , and that Mdm2 C305F/C305F cells retain a normal p53 response to DNA damage ( Figure 3) .
Next, we investigated p53 response to Act D in a more physiological setting of mouse skin, which has been extensively used to characterize effects of Act D on cell growth (Bates et al., 1968) . The dorsal skins of wild-type and Mdm2 C305F/C305F littermate mice were treated topically with a single dose of 1 mg Act D dissolved in 0.2 ml of acetone, which specifically inhibits ribosomal RNA synthesis with little effect on mRNA or protein synthesis in the mouse skin (Flamm et al., 1966) . Negative control mice and 8-Gy g-irradiated mice were mock treated with 0.2 ml of acetone. Eighteen hours after the treatment a portion of the skin was formalin fixed and the rest snap-frozen. Western blot analysis of epidermal lysates demonstrated that Act D-induced stabilization of p53 was diminished in Mdm2 C305F/C305F keratinocytes, whereas the response to g-irradiation remained intact ( Figure 4D ).
To determine Act D response on cell proliferation, we carried out cell cycle analysis. We treated early passage wild-type and Mdm2
C305F/C305F MEFs with 5 nM Act D for 18 hr and examined the percentage of cells in S phase by fluorescenceactivated cell sorting (FACS). The FACS analysis showed that the Mdm2 C305F/C305F cells had a weakened cell cycle arrest in response to Act D treatment ( Figure 4E ). Consistent results were obtained from BrdU (5-bromo-2-deoxyuridine) incorporation analysis of Act D treated dorsal mouse skins, inhibition of BrdU incorporation was less pronounced in Mdm2
keratinocytes than in wild-type keratinocytes ( Figure 4F ). We also examined if the Mdm2 C305F mutation confers resistance to 5-FU and MPA, two known inhibitors of ribosome biogenesis. We treated MEFs with 5-FU and MPA and determined p53 stabilization by Western blotting. Similar to the observations with Act D, p53 induction was attenuated in Mdm2 C305F/C305F MEFs in a gene dosage dependent manner ( Figure 4G ). Together, these results indicate that Mdm2 interaction with L5/L11 is important for transducing cellular stress signals that specifically impinge on ribosomal biogenesis, but not DNA damage, to p53.
Myc-Induced Lymphomagenesis Is Accelerated by Mdm2
C305F Mutation c-MYC upregulates ribosome biogenesis through direct transactivation of many nucleolar proteins involved in ribosome biogenesis (Ruggero and Pandolfi, 2003) . To determine the role of RP-Mdm2-p53 signaling in tumorigenesis, we crossed Mdm2 C305F/C305F mice with Em-Myc transgenic mice that constitutively express c-MYC in B cell lineage and develop B cell lymphoma at an early age (Adams et al., 1985) . Littermates animals (Em-Myc;Mdm2 
Mdm2
C305F/C305F animals, as well as from age-matched nontransgenic wildtype mice, and determined protein levels of L5 and L11. In agreement with recent studies showing c-MYC driving overexpression of ribosomal proteins (Boon et al., 2001; Coller et al., 2000; Menssen and Hermeking, 2002) , we found that the levels of L5 and L11 were highly elevated in tissues expressing Em-Myc, and the elevation is irrespective of the Mdm2 C305F mutation ( Figure 5C ). We also observed similar upregulation (Zhu et al., 2009 )of several other ribosomal proteins including L23, L26, S9, and S6 (data not shown). We noticed that the actin level appears to be lower in organs expressing Em-Myc when lysates containing equal amount of total protein were analyzed using immunoblotting. Therefore, in this case, actin-based loading control would only underestimate the extent of L5/L11 overexpression. Prior study demonstrates that inhibition of ribosome biogenesis induces translocation of L11 from nucleolus to nucleoplasm (Bhat et al., 2004) , we therefore investigated if c-MYC induced L5 and L11 overexpression could result in their nucleoplasmic accumulation, where they are in proximity with and can bind to Mdm2. We isolated spleens from 4-week-old nontumorbearing animals. At this age the spleens from Em-Myc transgenics are moderately hyperplastic, but still comparable to wild-type spleens in terms of organ size and morphology. We fractionated splenocyte lysates into total (TO), cytoplasmic (Cyto), nucleoplasmic (NP), and nucleolar (NO) fractions and examined L11 protein levels. Splenocytes isolated from tumorfree, young Em-Myc transgenics expressed a higher level of total L11 than do the nontransgenics ( Figure 5D , compare lanes 1 and 2). Importantly, L11 was more prominent in the NP fraction of Em-Myc transgenic splenocytes than of nontransgenic splenocytes ( Figure 5D , compare lanes 5 and 6). To further determine the consequence of increased L11 in the nucleoplasm, we carried out anti-Mdm2 IP-western assay with spleens isolated from nontumor-bearing Em-Myc;Mdm2 C305F/C305F mice and from control Em-Myc;Mdm2 +/+ littermates. As expected, Mdm2 interacted with L11 in lysates isolated from the EmMyc;Mdm2 +/+ splenocytes; whereas the L11 in Em-Myc;
C305F/C305F splenocytes, even though expressed to a higher level than in Em-Myc;Mdm2 +/+ splenocytes, showed very little interactions with Mdm2 ( Figure 5E ). Collectively, these data demonstrate that loss of L11-Mdm2 interaction due to the Mdm2 zinc finger C305F mutation accelerated oncogenic c-MYC-induced lymphomagenesis. The data also show that in c-MYC overexpressing cells L11 is highly expressed and enriched in the nucleus where it can interact with Mdm2, but not with Mdm2 C305F . Altogether, this suggests that disabling the L11-Mdm2 interaction can compromise, at least in part, p53 response to oncogenic c-MYC.
p19ARF Is Not Required for p53 Response to Ribosomal Stress
We have noticed that the median survival of Em-Myc; Mdm2 C305F/C305F mice (9 weeks; Figure 5A ) is very similar to that of Em-Myc;p19ARF À/À mice (8 weeks) (Eischen et al., 1999) .
We speculated that the p53 signaling mediated by RP-Mdm2 interaction and by p19ARF-Mdm2 interaction are parallel pathways both required for anti-Myc-induced tumorigenesis, elimination of either one results in accelerated tumor formation. Alternatively, the two pathways may function in a linear fashion, and mutations in Mdm2 that disrupt RP binding also affect p19ARF function. To gain insight into possible interlink between the two pathways, we first determined if p19ARF mediated oncogenic signaling is compromised by the Mdm2 mutation. To reduce individual variations duplicate mice were used in each sample group. We isolated splenic extracts from 4-week-old nontumor-bearing Em-Myc;Mdm2 +/+ and Em-Myc;
Mdm2
C305F/C305F transgenics, as well as from their nontransgenic counterparts. The extracts were immunoblotted for L11, p19ARF, and p53. In line with a previous study (Eischen et al., 1999) , Em-Myc expression resulted in elevated p19ARF expression in splenic B cells ( Figure 6A , lanes 5 and6). Elevated p19ARF expression was also observed in transgenic Mdm2 
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Function of the Mdm2 Zinc Finger in Tumorigenesis mediated induction of p19ARF does not required L11-Mdm2 binding. Importantly, we observed evident p53 induction in spleens of Em-Myc;Mdm2 +/+ transgenics, but less so in spleens of Em-Myc;Mdm2 C305F/C305F mice. This is consistent with a notion that the RP-Mdm2-p53 pathway is important in oncogenic c-MYC induction of p53.
Whereas sustained c-MYC expression elicits a p19ARF mediated p53 response, additional p19ARF independent mechanisms of c-MYC induction of p53 exist (Zindy et al., 1998) . Consistently, we found that both Mdm2 C305F/C305F and p19ARF À/À MEFs transiently expressing c-MYC had comparable elevated p53 levels, but was lower than that of wild-type MEFs ( Figure 6B ), suggesting that the RP-Mdm2-p53 and the p19ARF-Mdm2-p53 pathways act independently and are each contributing to c-MYC induction of p53. To further ascertain that the ribosomal stress-induced p53 is through a p19ARF independent mechanism, we investigated p53 induction in p19ARF À/À MEF cells treated with Act D. Western blotting demonstrated that in both wild-type and p19ARF À/À MEF cells p53 is induced similarly by a low level of Act D at comparable kinetics ( Figure 6C ). Furthermore, we noticed that Mdm2, a p53 target, was also induced with similar kinetics. Similar results were also obtained by treating cells with MPA ( Figure 6D ). Hence, the data indicate that p19ARF is not required for ribosomal inhibition-induced p53 activation. Finally, we examined Mdm2-p19ARF interaction in Act D treated Mdm2 C305F mutant MEFs. Act D treatment resulted in high-level expression of p53 and Mdm2 in wild-type but not Mdm2 C305F MEFs; the treatment also resulted in high-level expression of p53 and Mdm2 in p19ARF null MEFs ( Figure 6E, loading) . Immunoprecipitation demonstrated that Mdm2 C305F mutant protein interacts effectively with p19ARF, but not with L11 ( Figure 6E,  lanes 3 and 4) . Additionally, wild-type Mdm2 interacted with L11 in p19ARF null MEFs and the interaction was enhanced on Act D treatment ( Figure 6E , lanes 5 and 6). It is worth mentioning that the basal levels of p19ARF expression are slightly lower in Mdm2 C305F MEFs than in wild-type MEFs. Whether this is a variation of MEF cell clones or is directly related to Mdm2 C305F mutation remains to be determined.
DISCUSSION
A number of ribosomal proteins, including L5, L11, L23, L26, S3, and S7, have been shown to interact with and inhibit the E3 ligase function of Mdm2, thereby stabilizing and activating p53 (Chen et al., 2007; Jin et al., 2004; Lohrum et al., 2003; Ofir-Rosenfeld et al., 2008; Zhang et al., 2003; Zhu et al., 2009 ). The physiological significance of the RP-Mdm2 interaction, however, has not been previously studied in vivo. In this study, we generated and analyzed mice carrying a C305F knockin mutation in the Mdm2 zinc finger. The mutation disrupts the interaction of Mdm2 with L5 and L11. Several important observations have been made from this study.
An RP-Mdm2-p53 Signaling Pathway Sensing Inhibition of Ribosome Biogenesis
The generation of Mdm2 C305F mutant mice has allowed for a detailed in vivo characterization for the role of RP-Mdm2 binding in p53 response to ribosome biogenesis perturbations. Our data show that on DNA damage, the response of the mutant mice is indistinguishable from that of wild-type animals in terms of p53 activation, cell cycle arrest, and apoptosis. These data indicate that the integrity of the Mdm2 zinc finger and thus the binding of L5 and L11 are not required for p53 DNA damage response. In contrast, p53 response to treating animals with inhibitors that cause specifically inhibition of ribosomal biogenesis or nucleolar stress, but not DNA damage, is significantly compromised in mutant animals. The failure of Mdm2 C305F animals to respond to nucleolar stress is in agreement with previous in vitro studies, where knockdown of L11 results in an attenuated p53 response to the same forms of inhibitions (Bhat et al., 2004; Lohrum et al., 2003; Zhang et al., 2003) . It also corroborates our recent report that ectopically expressed Mdm2 C305F does not interact with L11, and that p53 activity that has been suppressed by ectopically expressed Mdm2
C305F cannot be restored by L11 overexpression (Lindstrom et al., 2007) . Also consistent with in vitro data, we have found that Mdm2 C305F retains ability to interact with L23 and p53 as well as with p19ARF. It seems that Mdm2 binding to L23, without binding to L5 and L11, is insufficient for the response of P53 to ribosomal stress. A recent study has shown that L11 cooperates with L5 to inhibit Mdm2. When coexpressed the inhibitory activity of L5 and L11 toward Mdm2 is enhanced (Horn and Vousden, 2008) . It remains to be studied if such a relationship exists in the context of L23. Nonetheless, the bulk of studies and available genetic models tend to favor L11 as the prime mediator of p53 ribosomal stress response via inhibition of Mdm2 (see below). At the concentrations used in our study (5 nM), Act D specifically inhibits RNA pol I-dependent transcription (IapalucciEspinoza and Franze-Fernandez, 1979; Perry and Kelley, 1970) causing nucleolar stress, without causing DNA damage. Consistently, genetic ablation of RNA Pol I transcription initiation factor tif-IA, which abrogates Pol I transcription, elicits a p53 response (Yuan et al., 2005) . In this sense, low dose Act D treatment is akin to genetic ablation of tif-IA. In fact, as is in the case with Act D treatment, ablation of tif-IA in MEFs evokes breakdown of the nucleolus, elicits the binding of L11 to Mdm2 and results in p53 activation (Yuan et al., 2005) . The Belly spot and tail (Bst) mice, which have a point mutation in the ribosomal protein gene rpl24, provide yet another genetic evidence for the existence of an RP-Mdm2-p53 signaling pathway. Mice heterozygous for rpl24 (Bst +/À mice) have impaired ribosomal biogenesis leading to various congenital abnormalities (Oliver et al., 2004) . Interestingly, impairment of ribosome biogenesis in the Bst +/À mice elicits a p53 response that is also mediated by L11 inhibition of Mdm2 (Barkic et al., 2009 ). In conjunction with the work presented herein, accumulating evidences from both in vitro and in vivo studies point to existence of a bona fide p53 responsive ribosomal biogenesis stress checkpoint ( Figure 7A ).
The L5/L11-Mdm2-p53 Signaling Pathway Is Required for Preventing Oncogenic c-MYC Induced Tumorigenesis
The proto-oncogene product c-MYC has been shown to directly regulate ribosome biogenesis through the transcription of genes encoding nucleolar proteins involved in ribosome biogenesis as well as some ribosomal proteins (Ruggero and Pandolfi, 2003) . However, it remains unknown whether c-MYC-driven ribosome biogenesis is directly responsible for tumor promotion. We postulated that the L11-Mdm2 interaction constitutes a checkpoint for superfluous production of ribosomal proteins resulting from oncogenic overexpression of c-MYC. To test this hypothesis, we generated and analyzed Em-Myc;Mdm2
C305F/C305F
mice. Em-Myc transgenic mice develop B cell lymphomas (Adams et al., 1985) , similar to those observed in human Burkitt's lymphomas bearing a translocated (t8;14) c-MYC allele (Alitalo et al., 1987) . Strikingly, we show that lymphomagenesis of EmMyc mice is greatly accelerated in the presence of Mdm2 C305F .
Mechanistically, c-MYC induces overexpression of L11, which accumulates in the nucleus and binds to Mdm2 but not Mdm2
C305F
. The accelerated morbidity imparted by the Mdm2 C305F mutation is thus likely due to the loss of L11 binding to Mdm2
. In regards to L23, it is clear that retention of L23 binding to Mdm2 C305F is insufficient to compensate for loss of L11 or L5 binding in deterring c-MYC lymphomagenesis in the Em-Myc;Mdm2 C305F/C305F mice. Moreover, although the genes encoding for L11 and L23 are c-MYC target genes, L11 is involved in a negative feedback loop with c-MYC, wherea L23 actually enables c-MYC to promote cell cycle progression Wanzel et al., 2008) . Collectively, these results indicate that the L11-Mdm2-p53 signaling plays an indispensable role in deterring c-MYC-mediated tumorigenesis.
p19ARF-Mdm2-p53 and L11-Mdm2-p53 Are Parallel Signaling Pathways Our results raise an interesting question with regard to cooperation between the p19ARF-Mdm2-p53 and the L11-Mdm2-p53 pathways. It is conceivable that p19ARF can impact ribosomal biogenesis through inhibiting the processing of pre-ribosomal RNA (Sugimoto et al., 2003) , at least in part, through its interaction with and inhibiting the function of B23 (NPM) (Itahana et al., 2003) , an endoribonuclease essential for pre-rRNA processing (Herrera et al., 1995; Savkur and Olson, 1998) . Consequently, such a p19ARF function can cause perturbation of ribosomal biogenesis and activate the L11-Mdm2-p53 pathway. However, whereas p19ARF can cause ribosome biogenesis stress per se, it is dispensable for the induction of p53 resulting from such stress, as demonstrated by the unaltered p53 response and L11-Mdm2 binding on nucleolar stress in p19ARF À/À MEFs. In addition, even though Mdm2 C305F/C305F MEFs lack p53 response to Act D treatment, the binding of Mdm2 C305F mutant protein to p19ARF remains intact.
Oncogenic c-MYC can induce p53 through p19ARF independent pathways (Zindy et al., 1998) . In support, c-MYC expression elicited ample p53 response in p19ARF null MEF cells ( Figure 6B ). Given the role of c-MYC in promoting ribosomal biogenesis, this p19ARF independent induction of p53 by c-MYC may very well be ribosomal protein mediated. This notion suggests that p53 can safeguard against c-MYC tumorigenesis via two independent signaling pathways, a p19ARF-Mdm2-p53 pathway and a ribosomal protein-Mdm2-p53 pathway (Figure 7B) . Accordingly, disruption of either one will accelerate c-MYC-induced tumor formation. This was illustrated by remarkably similar short survival time of Em-Myc;Mdm2
C305F/C305F
mice and Em-Myc;p19ARF À/À mice. Given the data showing similar susceptibility of Em-Myc;Mdm2 C305F/C305F and Em-Myc; p19ARF À/À transgenic animals to tumor development, one prediction will be that an even shorter latency of Myc-driven tumor formation might be found in compound mice carrying both Mdm2 C305F/C305F mutation and p19ARF deletion. In conclusion, our data support a model that the p19ARF-Mdm2-p53 and the RP-Mdm2-p53 pathways are independent, parallel pathways working together to protect cells from oncogenic c-MYCinduced tumorigenesis ( Figure 7B ). The Mdm2 C305F knockin mouse model provides evidence for a prevailing in vivo checkpoint, mediated by L11-Mdm2 interaction, to monitor the integrity of ribosome biogenesis and activate p53 when this process goes awry. The L11-Mdm2-p53 signaling pathway is not required for DNA damage induction of p53, in that the mutant mice respond to DNA damage and induce p53 activity as efficiently as their wild-type counterparts. Moreover, our data establish the L11-Mdm2-p53 pathway as an important in vivo barrier for defending against oncogenic c-MYC-induced tumorigenesis, parallel to the p19ARF-Mdm2-p53 signaling. p19ARF, through interaction with Mdm2, mediates a p53-dependent checkpoint in response to a broad range of oncogenic insults, including elevated expression of Myc, E2F1, RAS, E1A, and v-Abl (Sherr, 1998) . In this sense, it is conceivable that L11-Mdm2-p53 signaling also mediates a p53-dependent checkpoint in response to deregulated oncogenes that promote superfluous ribosome biogenesis. For instance, E2F1 specifically interacts with and enhances rRNA promoter activity through two E2F1-binding sequences (Ayrault et al., 2006) ; oncogenic RAS influences mTOR activity and thus protein translation through modulating the PI3K-Akt signaling cascade (Fingar and Blenis, 2004 A cysteine to phenylalanine substitution was introduced in codon 305 (C305F) using site-directed mutagenesis (TGT > TTT). A new Spe1 restriction site (ACT AGT) was generated at the same time (TGT ACC TCA > TTT ACT AGT). DNA isolated from G418-resistant ES cell colonies was subjected to BamH1 digestion followed by Southern blot analysis using a probe covering intron 9 between exons 9 and 10. The presence of the C305F substitution was further confirmed by PCR amplification of genomic DNA using primers flanking exon 12, followed by Spe1 digestion. One positive clone was injected into blastocysts, and transferred into pseudopregnant female recipients. Germline transmission was confirmed by Southern blot and PCR analysis. Neomycin selection marker was deleted by crossing germline transmitted Mdm2
mice with Ella-Cre transgenic mice (Jackson Laboratories, stock number 003724). The resulting males were mated with C57BL/6 females and backcrossed to C57BL/6 for five generations.
Mouse Experiments
Mice were bred and maintained strictly under protocol (07-056) approved by the Institutional Animal Care and Use Committee in the University of North Carolina Animal Care Facility. For BrdU incorporation experiment, mice were injected intraperitoneally with BrdU (50 mg/g body weight) 30 min before euthanasia. BrdU incorporation was detected by immunohistochemical staining of paraffin-embedded tissue sections with mouse anti-BrdU (Ab-2) monoclonal antibody (Calbiochem, San Diego, CA), biotin-conjugated anti-mouse antibody (Vector Laboratories, Burlingame, CA) and an avidin-biotin-peroxidase kit (Vectastain Elite, Vector Laboratories) with diaminobenzidine as a chromogen. The percentage of BrdU positive cells from the total number of interfollicular keratinocytes in 200 mm fields and 15 fields per mouse were quantified. For mouse skin treatments, mice from each genotype were shaven 24 hr before treatment. The dorsal skin was treated topically for 18 hr with a single dose of Act D at 1 ug/200 ul in acetone or acetone only. For apoptosis studies, TUNEL assay was carried out using an ApopTag Peroxidase In Situ Apoptosis Detection Kit (Calbiochem, S7100). For c-MYC-mediated tumorigenesis study, Mdm2 C305F/C305F females were bred with Em-Myc transgenic males to obtain Em-Myc;Mdm2 +/C305F offspring, which were then crossed with Mdm2 C305F/C305F mice to obtain Em-Myc;Mdm2 C305F/C305F compound mice. Em-Myc mice were purchased from Jackson Laboratory (002728). For survival study, mice were palpated regularly for early signs of inguinal lymph node enlargement and monitored for tumor progression and signs of morbidity. Moribund mice were humanely euthanized by CO 2 asphyxiation followed by a second method to ensure euthanasia. Mouse tumors and organs were fixed in formalin for histopathology and snap frozen for protein and RNA extraction.
Cell Culture
Primary mouse embryo fibroblasts (MEF) were isolated on embryonic (E) day 13.5 and grown in a 37 C incubator with 5% CO 2 in DMEM supplied with , and p19ARF À/À MEF cells were infected with retroviruses expressing c-MYC or pBabe control vector and selected with puromycin (2.5 ug/ml) for 3 days. Retrovirus infected MEFs were then allowed to recover for 48 hr and harvested for analysis.
Protein Analysis
For western blot, MEF cells were lysed with 0.5% NP-40 lysis buffer for straight westerns or 0.1% NP-40 lysis buffer for coimmunoprecipitation experiments. For mouse tissue protein extraction, spleens, thymus, and lymphoma tissues were ground by pestle and mortar with liquid N 2 and the protein was extracted with 0.5% NP-40 lysis buffer. For protein analysis of epidermal keratinocytes, the epidermal skin layer was scraped off excised skin using a razor blade and extracted with 0.5% NP-40 lysis buffer. To assess the half-life of p53 and Mdm2, low passage MEF cells were treated with cycloheximide (50 ug/ml), chased for the indicated time points, and harvested with SDS lysis buffer (2% SDS, 10% glycerol, 50 mM Tris). Mouse monoclonal anti Mdm2 (2A10 and 4B11, Calbiochem), p53 (NCL-505, Novocastra; DO-1, Lab Vision/ Neomarkers), actin (MAB1501, Chemicon International), goat polyclonal anti p53 (FL-393; Santa Cruz), and rat polyclonal anti p19ARF (Santa Cruz) antibodies were purchased commercially. Rabbit polyclonal antibodies to p21 were gifts from Dr. Yue Xiong (UNC-Chapel Hill). Rabbit polyclonal antibodies to L5 and L11 were made in house and previously described (Lindstrom et al., 2007) .
Cellular Fractionation
Protocol for nucleolar fractionation was adapted from a previously described method by Muramatsu et al. (1974) . Freshly harvested mouse spleens were mechanically disassociated between two glass microscope slides. Large debris was allowed to settle and single cell suspension was centrifuged at 200 3 g for 10 min and washed 23 with RPMI (Roswell Park Memorial Institute) medium. Red blood cell lysis was carried out using NH 4 Cl lysis buffer (0.75% NH 4 Cl, 0.017 M Tris-HCl, pH 7.2) for 5 min at room temperature. Splenocytes were resuspended in 1 ml of RSB buffer (10 mM HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM DTT) and placed on ice for 10 min. Cell membranes were then broken using a Dounce homogenizer (tight pestle A). Nuclei (pellet) were collected by centrifugation at 218 3 g for 5 min and resuspended in 3 ml of 0.25 M sucrose/10 mM MgCl 2 and overlaid onto 3 ml of 0.88 M sucrose/ 0.05 mM MgCl 2 and purified by centrifugation at 1430 3 g for 10 min. The pelleted nuclei were resuspended in 2 ml of 0.34 M sucrose/0.05 mM MgCl 2 and sonicated for 60 s with 10-s intervals. The sonicated cell lysate was then overlaid onto 3 ml of 0.88 M sucrose/0.05 mM MgCl 2 and centrifuged at 3000 3 g for 10 min. The pellet contained the purified nucleoli and the supernatant represented the nucleoplasmic fraction. Protease inhibitor cocktail was added freshly to all buffers before use.
Statistical Analysis
Statistical analysis was carried out using GraphPad Prism 4 Software (GraphPad Software, San Diego, CA). For Em-Myc tumorigenesis experiments a Kaplan-Meier survival curve was carried out. A one-way analysis of variance test with Tukey's multiple comparison posttest was carried out for BrdU incorporation experiments.
